Dr. Elizabeth Pisani is the convenor of the MedsWatch group. She’s an epidemiologist by training and a political economist by persuasion, and is most interested in the messy places where biomedical evidence clashes with politics, money and culture. She has zero hours contracts and/or honorary appointments at Erasmus School of Health Policy and Management, the George Institute of Global Health, the London School of Hygiene and Tropical Medicine and King’s College London. She’s a card-carrying member of the global health mafia, and sometimes does work for governments and organisations such as the World Bank and the WHO .
Amalia Hasnida is a public health researcher at Erasmus School of Health Policy and Management (ESHPM), Erasmus University, Rotterdam. A microbiologist by training, Amalia started her career in the multinational pharmaceutical industry in Indonesia, responsible for market access and government affairs. She continued her masters degree in international public health at Vrije Universiteit Amsterdam in The Netherlands. After completing her studies in 2017, she joined the informal MedsWatch coalition as a lead researcher for an Indonesian case study of political and economic drivers of substandard and falsified medicines. Currently, she is developing a market risk-based flagging tool to strengthen regulatory post-market surveillance in low and middle-income countries; this project is part of the Fellowship in Quality of Medical Products supported by the United States of Pharmacopeial (USP) Convention Quality Institute. She is based in Jakarta, Indonesia.
Koray Parmaksiz from Erasmus University, Rotterdam;
Dr. Anggriani chairs the Center for Pharmaceutical Policy at Universitas Pancasila in Jakarta, and is a Senior Lecturer in the Clinical and Community Pharmacy Section. She an Evaluator on the National Medicines Evaluation Committee at the Indonesia’s national medicine regulator, and also regularly provides advice on pharmaceutical policy to the Ministry of Health, UNDP, WHO and other global health organisation. She’s interested in the relationship between price, availability and accessibility of medicines, and their impact on quality, especially in the context of Indonesia’s national health insurance system, which is one of the world’s largest.
Mawadati Rahmi from Universitas Pancasila, Jakarta;
Steven Harsono, Yee-Theng Ng and Annie Wang from IQVIA Public Health, Singapore.